National Cancer Institute; Notice of Closed Meetings, 53491-53492 [2018-23069]

Download as PDF khammond on DSK30JT082PROD with NOTICES Federal Register / Vol. 83, No. 205 / Tuesday, October 23, 2018 / Notices Bethesda, MD 20892, 301–827–2864, maskerib@mail.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Biobehavioral Applications in Ethology and Substance Abuse. Date: November 15, 2018. Time: 12:00 p.m. to 4:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Andrea B. Kelly, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3182, MSC 7770, Bethesda, MD 20892, (301) 455– 1761, kellya2@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; AREA Application Review. Date: November 19, 2018. Time: 3:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Katherine M. Malinda, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4140, MSC 7814, Bethesda, MD 20892, 301–435– 0912, Katherine_Malinda@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; AREA Application Review. Date: November 19, 2018. Time: 3:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Larry Pinkus, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4132, MSC 7802, Bethesda, MD 20892, (301) 435– 1214, pinkusl@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research; 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) DEPARTMENT OF HEALTH AND HUMAN SERVICES Dated: October 17, 2018. David D. Clary, Program Analyst, Office of Federal Advisory Committee Policy. Name of Committee: National Cancer Institute Special Emphasis Panel; SEP–2: NCI Clinical and Translational R21 and Omnibus R03. Date: November 7, 2018. Time: 11:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute, Shady Grove, 9609 Medical Center Drive, Room 7W112, Rockville, MD 20850 (Telephone Conference Call). [FR Doc. 2018–23035 Filed 10–22–18; 8:45 am] BILLING CODE 4140–01–P VerDate Sep<11>2014 20:20 Oct 22, 2018 Jkt 247001 National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the Diabetes, Endocrinology and Metabolic Diseases B Subcommittee, October 24, 2018, 05:30 p.m. to October 26, 2018, 04:00 p.m., Residence Inn Capital View, 2850 South Potomac Avenue, Arlington, VA, 22202 which was published in the Federal Register on September 12, 2018, 64 FR 46178. The meeting is being amended to reflect location change. The new meeting location is the Renaissance Washington DC Downtown, 999 9th Street NW, Washington, DC 20001. The meeting is closed to the public. Dated: October 17, 2018. David D. Clary, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–23033 Filed 10–22–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 53491 Contact Person: Jennifer C. Schiltz, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W112, Bethesda, MD 20892–9750, 240–276–5864, jennifer.schiltz@ nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Collaborative Human Tissue Network (CHTN) (UM1). Date: November 14, 2018. Time: 10:30 a.m. to 1:30 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute, Shady Grove, 9609 Medical Center Drive, Room 7W122, Rockville, MD 20850 (Telephone Conference Call). Contact Person: Sanita Bharti, Ph.D., Scientific Review Officer, Research Program Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W122, Bethesda, MD 20892–9750, 240–276–5909, sanitab@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; SBIR Phase IIB Bridge Awards. Date: November 15, 2018. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute, Shady Grove, 9609 Medical Center Drive, Room 7W114, Rockville, MD 20850 (Telephone Conference Call). Contact Person: Jeffrey E. DeClue, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W114, Bethesda, MD 20892– 9750, 240–276–6371, decluej@mail.nih.gov. Name of Committee: National Cancer Institute Initial Review Group Subcommittee A—Cancer Centers. Date: November 29, 2018. Time: 8:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817. Contact Person: Shamala K. Srinivas, Ph.D., Scientific Review Officer, Office of Referral, Review, and Program Coordination, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W530, Bethesda, MD 20892– 9750, 240–276–6442, ss537t@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Cancer Center Support Grant (P30). Date: November 29, 2018. Time: 4:30 p.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817 (Telephone Conference Call). Contact Person: Shamala K. Srinivas, Ph.D., Scientific Review Officer, Office of Referral, Review, and Program Coordination, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center E:\FR\FM\23OCN1.SGM 23OCN1 53492 Federal Register / Vol. 83, No. 205 / Tuesday, October 23, 2018 / Notices Drive, Room 7W530, Bethesda, MD 20892– 9750, 240–276–6442, ss537t@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: October 17, 2018. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–23069 Filed 10–22–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the Frederick National Laboratory Advisory Committee to the National Cancer Institute, October 29, 2018, 09:30 a.m. to October 29, 2018, 04:30 p.m., National Cancer Institute Shady Grove, 9609 Medical Center Drive, TE406, Rockville, MD, 20850 which was published in the Federal Register on October 11, 2018, 83 FR 51468. The meeting notice is amended to change the start and end time of the meeting from 9:30 a.m.–4:30 p.m. to 9:00 a.m.–4:00 p.m. on October 29, 2018. The meeting is open to the public. Dated: October 17, 2018. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–23070 Filed 10–22–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration khammond on DSK30JT082PROD with NOTICES Agency Information Collection Activities: Proposed Collection; Comment Request In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 concerning opportunity for public comment on proposed collections of information, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish periodic summaries of VerDate Sep<11>2014 20:20 Oct 22, 2018 Jkt 247001 proposed projects. To request more information on the proposed projects or to obtain a copy of the information collection plans, call the SAMHSA Reports Clearance Officer on (240) 276– 1243. Comments are invited on: (a) Whether the proposed collections of information are necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Proposed Project: Community Mental Health Services Block Grant and Substance Abuse Prevention and Treatment Block Grant FY 2020–2021 Plan and Report Guidance and Instructions (OMB No. 0930–0168)— Extension The Substance Abuse and Mental Health Services Administration (SAMHSA) is requesting approval from the Office of Management and Budget (OMB) for an extension of the 2018–19 Community Mental Health Services Block Grant (MHBG) and Substance Abuse Prevention and Treatment Block Grant (SABG) Plan and Report Guidance and Instructions. Currently, the SABG and the MHBG differ on a number of their practices (e.g., data collection at individual or aggregate levels) and statutory authorities (e.g., method of calculating MOE, stakeholder input requirements for planning, set asides for specific populations or programs, etc.). Historically, the Centers within SAMHSA that administer these block grants have had different approaches to application requirements and reporting. To compound this variation, states have different structures for accepting, planning, and accounting for the block grants and the prevention set aside within the SABG. As a result, how these dollars are spent and what is known about the services and clients that receive these funds varies by block grant and by state. SAMHSA has conveyed that block grant funds must be directed toward four purposes: (1) To fund priority treatment and support services for individuals without insurance or who cycle in and out of health insurance coverage; (2) to fund those priority treatment and support services not PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 covered by Medicaid, Medicare or private insurance offered through the exchanges and that demonstrate success in improving outcomes and/or supporting recovery; (3) to fund universal, selective and targeted prevention activities and services; and (4) to collect performance and outcome data to determine the ongoing effectiveness of behavioral health prevention, treatment and recovery support services and to plan the implementation of new services on a nationwide basis. To help states meet the challenges of 2020 and beyond, and to foster the implementation and management of an integrated physical health, mental health and addiction service system, SAMHSA has established standards and expectations that will lead to an improved system of care for individuals with or at risk of mental and substance use disorders. Therefore, this application package continues to fully exercise SAMHSA’s existing authority regarding states’, territories’ and the Red Lake Band of the Chippewa Tribe’s (subsequently referred to as ‘‘states’’) use of block grant funds as they fully integrate behavioral health services into the broader health care continuum. Consistent with previous applications, the FY 2020–2021 application has sections that are required and other sections where additional information is requested. The FY 2020–2021 application requires states to submit a face sheet, a table of contents, a behavioral health assessment and plan, reports of expenditures and persons served, an executive summary, and funding agreements and certifications. In addition, SAMHSA is requesting information on key areas that are critical to the states success in addressing health care integration. Therefore, as part of this block grant planning process, SAMHSA is asking states to identify both their promising or effective strategies as well as their technical assistance needs to implement the strategies they identify in their plans for FYs 2020 and 2021. To facilitate an efficient application process for states, SAMHSA utilized the questions and requests for clarification from representatives from SMHAs and SSAs to inform the proposed changes to the block grants. Based on these discussions with states, SAMHSA is proposing de minimis changes to the block grant program, consisting of updated dates and clarification to instructions. While the statutory deadlines and block grant award periods remain unchanged, SAMHSA encourages states to turn in their application as early as E:\FR\FM\23OCN1.SGM 23OCN1

Agencies

[Federal Register Volume 83, Number 205 (Tuesday, October 23, 2018)]
[Notices]
[Pages 53491-53492]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-23069]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; SEP-2: NCI Clinical and Translational R21 and Omnibus R03.
    Date: November 7, 2018.
    Time: 11:00 a.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute, Shady Grove, 9609 Medical 
Center Drive, Room 7W112, Rockville, MD 20850 (Telephone Conference 
Call).
    Contact Person: Jennifer C. Schiltz, Ph.D., Scientific Review 
Officer, Special Review Branch, Division of Extramural Activities, 
National Cancer Institute, NIH, 9609 Medical Center Drive, Room 
7W112, Bethesda, MD 20892-9750, 240-276-5864, 
[email protected].

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; Collaborative Human Tissue Network (CHTN) (UM1).
    Date: November 14, 2018.
    Time: 10:30 a.m. to 1:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute, Shady Grove, 9609 Medical 
Center Drive, Room 7W122, Rockville, MD 20850 (Telephone Conference 
Call).
    Contact Person: Sanita Bharti, Ph.D., Scientific Review Officer, 
Research Program Review Branch, Division of Extramural Activities, 
National Cancer Institute, NIH, 9609 Medical Center Drive, Room 
7W122, Bethesda, MD 20892-9750, 240-276-5909, [email protected].

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; SBIR Phase IIB Bridge Awards.
    Date: November 15, 2018.
    Time: 10:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute, Shady Grove, 9609 Medical 
Center Drive, Room 7W114, Rockville, MD 20850 (Telephone Conference 
Call).
    Contact Person: Jeffrey E. DeClue, Ph.D., Scientific Review 
Officer, Research Technology and Contract Review Branch, Division of 
Extramural Activities, National Cancer Institute, NIH, 9609 Medical 
Center Drive, Room 7W114, Bethesda, MD 20892-9750, 240-276-6371, 
[email protected].

    Name of Committee: National Cancer Institute Initial Review 
Group Subcommittee A--Cancer Centers.
    Date: November 29, 2018.
    Time: 8:00 a.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, 
Bethesda, MD 20817.
    Contact Person: Shamala K. Srinivas, Ph.D., Scientific Review 
Officer, Office of Referral, Review, and Program Coordination, 
Division of Extramural Activities, National Cancer Institute, NIH, 
9609 Medical Center Drive, Room 7W530, Bethesda, MD 20892-9750, 240-
276-6442, [email protected].

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; Cancer Center Support Grant (P30).
    Date: November 29, 2018.
    Time: 4:30 p.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, 
Bethesda, MD 20817 (Telephone Conference Call).
    Contact Person: Shamala K. Srinivas, Ph.D., Scientific Review 
Officer, Office of Referral, Review, and Program Coordination, 
Division of Extramural Activities, National Cancer Institute, NIH, 
9609 Medical Center

[[Page 53492]]

Drive, Room 7W530, Bethesda, MD 20892-9750, 240-276-6442, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: October 17, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-23069 Filed 10-22-18; 8:45 am]
 BILLING CODE 4140-01-P